Association of a characteristic membrane pattern of annexin A2 with high invasiveness and nodal status in colon adenocarcinoma

Tristante, Elena; Martínez, Carlos; Jiménez, Sofía; Mora, Lucia; Carballo, Fernando; Martínez-Lacaci, Isabel; Torre‐Minguela, Carlos de

doi:10.1016/j.trsl.2015.02.006

Cited by 16 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature search revealed 2728 publications ( Figure 2 ). Of the 143 included for full text review, 34 were ultimately included in the meta-analysis ( Hase et al , 1993 ; Ueno et al , 2002a ; Okuyama et al , 2003a , 2003b ; Ueno et al , 2004 ; Prall et al , 2005 ; Wang et al , 2005 ; Yasuda et al , 2007 ; Kanazawa et al , 2008 ; Nakamura et al , 2008 ; Yamauchi et al , 2008 ; Lugli et al , 2009 ; Ogawa et al , 2009 ; Wang et al , 2009 ; Homma et al , 2010 ; Kajiwara et al , 2010 ; Komori et al , 2010 ; Tateishi et al , 2010 ; Akishima-Fukasawa et al , 2011 ; Reggiani Bonetti et al , 2011 ; Betge et al , 2012 ; Nakadoi et al , 2012 ; Sert Bektas et al , 2012 ; Zlobec et al , 2012 ; Wada et al , 2013 ; Huh et al , 2014 ; Lai et al , 2014 ; Nishida et al , 2014 ; Ryu et al , 2014 ; Gilardoni et al , 2015 ; Macias-Garcia et al , 2015 ; Miyachi et al , 2015 ; Tristante et al , 2015 ; Barresi et al , 2016 ). There were a total of 7821 patients included for analysis, with study groups ranging from 58 to 1114 patients.…”

Section: Resultsmentioning

confidence: 99%

Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer

et al. 2016

View full text Add to dashboard Cite

Background:Tumour budding is a histological finding in epithelial cancers indicating an unfavourable phenotype. Previous studies have demonstrated that it is a negative prognostic indicator in colorectal cancer (CRC), and has been proposed as an additional factor to incorporate into staging protocols.Methods:A systematic review of papers until March 2016 published on Embase, Medline, PubMed, PubMed Central and Cochrane databases pertaining to tumour budding in CRC was performed. Study end points were the presence of lymph node metastases, recurrence (local and distal) and 5-year cancer-related death.Results:A total of 7821 patients from 34 papers were included, with a mean rate of tumour budding of 36.8±16.5%. Pooled analysis suggested that specimens exhibiting tumour budding were significantly associated with lymph node positivity (OR 4.94, 95% CI 3.96–6.17, P<0.00001), more likely to develop disease recurrence over the time period (OR 5.50, 95% CI 3.64–8.29, P<0.00001) and more likely to lead to cancer-related death at 5 years (OR 4.51, 95% CI 2.55–7.99, P<0.00001).Conclusions:Tumour budding in CRC is strongly predictive of lymph node metastases, recurrence and cancer-related death at 5 years, and its incorporation into the CRC staging algorithm will contribute to more effective risk stratification.

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Annexin A2 in the cell membrane is a characteristic for tumours with high invasiveness. This ability to invade tissue shows how Annexin A2 could affect lymph node metastasis (52,53). Annexin A2 has also been shown to be important for the effect of progastrins and gastrins, hereby partially mediating the effect of growth factors on colon cancer cells (95).…”

Section: Gastroenterological Cancers Colorectal Cancer (Crc)mentioning

confidence: 97%

Annexin A2 and cancer: A systematic review

et al. 2017

View full text Add to dashboard Cite

Annexin A2 is a 36-kDa protein interfering with multiple cellular processes especially in cancer progression. The present review aimed to show the relations between Annexin A2 and cancer. A systematic search for studies investigating cancer and Annexin A2 expression was conducted using PubMed. Acute lymphoblastic leukaemia, acute promyelocytic leukaemia, clear cell renal cell carcinoma, breast, cervical, colorectal, endometrial, gastric cancer, glioblastoma, hepatocellular carcinoma, lung, multiple myeloma, oesophageal squamous cell carcinoma, ovarian cancer, pancreatic duct adenocarcinoma, prostate cancer and urothelial carcinoma were evaluated. Annexin A2 expression correlates with resistance to treatment, binding to the bone marrow, histological grade and type, TNM-stage and shortened overall survival. The regulation of Annexin A2 is of interest due to its potential as target for a more individualized cancer management.

show abstract

“…Evaluation of ANXA2 protein expression in renal cell carcinoma (RCC) patients was associated with not only clinical outcome but also correlated with Fuhrman grade (tumor differentiation) . Colorectal and cholangiocarcinoma patients exhibited increased ANX A2 expression, specifically on the cell surface, was associated with poor prognosis, lymphatic invasion and metastasis . Patients with nonsmall cell lung cancer (NSCLC) demonstrated increased ANX A2 protein overexpression.…”

Section: Introductionmentioning

confidence: 99%

Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers

Sharma

2018

Intl Journal of Cancer

View full text Add to dashboard Cite

ANX A2 is an important member of annexin family of proteins expressed on surface of endothelial cells (ECs), macrophages, mononuclear cells and various types of cancer cells. It exhibits high affinity binding for calcium (Ca ) and phospholipids. ANX A2 plays an important role in many biological processes such as endocytosis, exocytosis, autophagy, cell-cell communications and biochemical activation of plasminogen. On the cell surface ANX A2 organizes the assembly of plasminogen (PLG) and tissue plasminogen activator (tPA) for efficient conversion of PLG to plasmin, a serine protease. Proteolytic activity of plasmin is required for activation of inactive pro-metalloproteases (pro-MMPs) and latent growth factors for their biological actions. These activation steps are critical for degradation of extracellular matrix (ECM) and basement proteins (BM) for cancer cell invasion and metastasis. Increased expression of ANX A2 protein/gene has been correlated with invasion and metastasis in a variety of human cancers. Moreover, clinical studies have positively correlated ANX A2 protein expression with aggressive cancers and with resistance to anticancer drugs, shorter disease-free survival (DFS), and worse overall survival (OS). The mechanism(s) by which ANX A2 regulates cancer invasion and metastasis are beginning to emerge. Investigators used various technologies to target ANX A2 in preclinical model of human cancers and demonstrated exciting results. In this review article, we analyzed existing literature concurrent with our own findings and provided a critical overview of ANX A2-dependent mechanism(s) of cancer invasion and metastasis.

show abstract

Association of a characteristic membrane pattern of annexin A2 with high invasiveness and nodal status in colon adenocarcinoma

Cited by 16 publications

References 29 publications

Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer

Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer

Annexin A2 and cancer: A systematic review

Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers

Contact Info

Product

Resources

About